141 related articles for article (PubMed ID: 29277318)
1. T2E (TMPRSS2-ERG) fusion transcripts are associated with higher levels of AMACR mRNA and a subsequent prostate cancer diagnosis in patients with atypical small acinar proliferation.
Eryilmaz IE; Kordan Y; Vuruskan BA; Kaygısız O; Tunca B; Cecener G
Gene; 2018 Mar; 645():69-75. PubMed ID: 29277318
[TBL] [Abstract][Full Text] [Related]
2. RNA-based markers in biopsy cores with atypical small acinar proliferation: Predictive effect of T2E fusion positivity and MMP-2 upregulation for a subsequent prostate cancer diagnosis.
Eryilmaz IE; Aytac Vuruskan B; Kaygısız O; Egeli U; Tunca B; Kordan Y; Cecener G
Prostate; 2019 Feb; 79(2):195-205. PubMed ID: 30294801
[TBL] [Abstract][Full Text] [Related]
3. High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.
Box A; Alshalalfa M; Hegazy SA; Donnelly B; Bismar TA
Tumour Biol; 2016 Sep; 37(9):12287-12299. PubMed ID: 27271990
[TBL] [Abstract][Full Text] [Related]
4. The diagnostic use of ERG in resolving an "atypical glands suspicious for cancer" diagnosis in prostate biopsies beyond that provided by basal cell and α-methylacyl-CoA-racemase markers.
Shah RB; Tadros Y; Brummell B; Zhou M
Hum Pathol; 2013 May; 44(5):786-94. PubMed ID: 23158212
[TBL] [Abstract][Full Text] [Related]
5. Foamy gland carcinoma of the prostate in needle biopsy: incidence, Gleason grade, and comparative α-methylacyl-CoA racemase vs. ERG expression.
Warrick JI; Humphrey PA
Am J Surg Pathol; 2013 Nov; 37(11):1709-14. PubMed ID: 23797726
[TBL] [Abstract][Full Text] [Related]
6. Detection of alpha-methylacyl-coenzyme-A racemase transcripts in blood and urine samples of prostate cancer patients.
Zehentner BK; Secrist H; Zhang X; Hayes DC; Ostenson R; Goodman G; Xu J; Kiviat M; Kiviat N; Persing DH; Houghton RL
Mol Diagn Ther; 2006; 10(6):397-403. PubMed ID: 17154657
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG status.
Mancarella C; Casanova-Salas I; Calatrava A; García-Flores M; Garofalo C; Grilli A; Rubio-Briones J; Scotlandi K; López-Guerrero JA
BMC Cancer; 2017 May; 17(1):367. PubMed ID: 28545426
[TBL] [Abstract][Full Text] [Related]
8. [Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].
Dai MJ; Chen LL; Zheng YB; Chen W; Tao ZH; Weng ZL; Wu XL; Li CD; Chen ZG; Chen XD; Shi SB
Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(10):669-73. PubMed ID: 18642766
[TBL] [Abstract][Full Text] [Related]
9. Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.
Schostak M; Miller K; Krause H; Schrader M; Kempkensteffen C; Kollermann J
Cancer Detect Prev; 2006; 30(5):449-54. PubMed ID: 17067752
[TBL] [Abstract][Full Text] [Related]
10. Atypical small acinar proliferation (ASAP): Is a repeat biopsy necessary ASAP? A multi-institutional review.
Leone A; Gershman B; Rotker K; Butler C; Fantasia J; Miller A; Afiadata A; Amin A; Zhou A; Jiang Z; Sebo T; Mega A; Schiff S; Pareek G; Golijanin D; Yates J; Karnes RJ; Renzulli J
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):68-71. PubMed ID: 26857145
[TBL] [Abstract][Full Text] [Related]
11. Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.
Alinezhad S; Väänänen RM; Ochoa NT; Vertosick EA; Bjartell A; Boström PJ; Taimen P; Pettersson K
BMC Urol; 2016 Feb; 16():10. PubMed ID: 26928323
[TBL] [Abstract][Full Text] [Related]
12. Aspirin and NSAID use in association with molecular subtypes of prostate cancer defined by TMPRSS2:ERG fusion status.
Wright JL; Chéry L; Holt S; Lin DW; Luedeke M; Rinckleb AE; Maier C; Stanford JL
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):53-6. PubMed ID: 26503111
[TBL] [Abstract][Full Text] [Related]
13. TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer.
Kron KJ; Murison A; Zhou S; Huang V; Yamaguchi TN; Shiah YJ; Fraser M; van der Kwast T; Boutros PC; Bristow RG; Lupien M
Nat Genet; 2017 Sep; 49(9):1336-1345. PubMed ID: 28783165
[TBL] [Abstract][Full Text] [Related]
14. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
Winnes M; Lissbrant E; Damber JE; Stenman G
Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
[TBL] [Abstract][Full Text] [Related]
15. Individualized detection of TMPRSS2-ERG fusion status in prostate cancer: a rank-based qualitative transcriptome signature.
Li Y; Su H; Liu K; Zhao Z; Wang Y; Chen B; Xia J; Yuan H; Huang DS; Gu Y
World J Surg Oncol; 2024 Feb; 22(1):49. PubMed ID: 38331878
[TBL] [Abstract][Full Text] [Related]
16. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer.
Rubin MA; Zhou M; Dhanasekaran SM; Varambally S; Barrette TR; Sanda MG; Pienta KJ; Ghosh D; Chinnaiyan AM
JAMA; 2002 Apr; 287(13):1662-70. PubMed ID: 11926890
[TBL] [Abstract][Full Text] [Related]
17. Obesity and Prostate Cancer Risk According to Tumor TMPRSS2:ERG Gene Fusion Status.
Egbers L; Luedeke M; Rinckleb A; Kolb S; Wright JL; Maier C; Neuhouser ML; Stanford JL
Am J Epidemiol; 2015 May; 181(9):706-13. PubMed ID: 25852077
[TBL] [Abstract][Full Text] [Related]
18. A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer.
Ouyang B; Bracken B; Burke B; Chung E; Liang J; Ho SM
J Urol; 2009 Jun; 181(6):2508-13; discussion 2513-4. PubMed ID: 19371911
[TBL] [Abstract][Full Text] [Related]
19. Utility of ERG versus AMACR expression in diagnosis of minimal adenocarcinoma of the prostate in needle biopsy tissue.
Andrews C; Humphrey PA
Am J Surg Pathol; 2014 Jul; 38(7):1007-12. PubMed ID: 24705308
[TBL] [Abstract][Full Text] [Related]
20. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
Luo J; Zha S; Gage WR; Dunn TA; Hicks JL; Bennett CJ; Ewing CM; Platz EA; Ferdinandusse S; Wanders RJ; Trent JM; Isaacs WB; De Marzo AM
Cancer Res; 2002 Apr; 62(8):2220-6. PubMed ID: 11956072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
